[New therapeutic trends in thalassemia: oral chelating agents].
The future therapeutic strategy for decreasing iron overload in poly-transfused patients will include oral chelation. The product currently undergoing the most intensive experimentation is Ll (1,2-dimethyl-3-hydroxypyrid-4-one). We report here a short-term efficacy study carried out in 10 thalassemic transfusion-dependent pediatric volunteer patients, already closely followed in our Day Hospital, after having provided their informed consent. In our study Ll, when compared to Desferrioxamine, was clearly efficacious and safe.
Carnelli
V
V
Istituto di Clinica Pediatrica, Università degli Studi, Cattedra di Ematologia Pediatrica, Milano, Italia.
Terzoli
S
S
Fossati
G
G
Careddu
G
G
Perri
M
M
Pedrotti
L
L
Mirra
N
N
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002648:Child; D000077543:Deferiprone; D003676:Deferoxamine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007258:Informed Consent; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008297:Male; D011728:Pyridones / Q000008:administration & dosage*; D013789:Thalassemia / Q000188:drug therapy*
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D003676:Deferoxamine
Nuove prospettive terapeutiche per la thalassemia: i chelanti orali.